retatrutide cause cancer Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and STUDY: Novel “Triagonist” Retatrutide Resolved

Semaglutide the active ingredient in Ozempic and Wegovy activates receptors for glucagon-like peptide-1 (GLP-1), a gut hormone that reduces appetite and promotes fullness by slowing the rate at which food leaves the stomach

The only approved oral GLP-1 drug is Rybelsus, a pill for type 2 diabetes from Novo Nordisk, the same company that makes semaglutide and sells it as Ozempic and Wegovy

Weight loss has been shown to reverse this inflammatory profile, decreasing circulating pro-inflammatory markers and increasing levels of adiponectin, an anti-inflammatory adipokine with potential neuroprotective effects [126]

Korean Journal of Anesthesiology

Food and Drug Administration approved it as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023, and it is authorized by the European Medicines Agency as well

While Ozempic can be combined with other diabetes medications, such as insulin and metformin, it is essential to monitor your blood sugar levels, especially if you are taking higher doses of these medications